Comment on “adjuvant bacillus Calmette-Gu'erin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-naïve high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study”

International Immunopharmacology 2026

View at publisher

Authors: Haonan Jin

DOI: 10.1016/j.intimp.2026.116312

Cited by: 0

References: 3

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Cancer Immunotherapy and Biomarkers Urinary Tract Infections Management

References 3